Zura Bio to present data exploring expanded potential of tibulizumab

Zura Bio announced it will present data from its tibulizumab program exploring the clinical potential of the dual-pathway antibody in Sjogren’s syndrome and rheumatoid arthritis at EULAR 2024, June 12-15 in Vienna. “We are excited to present translational data from our tibulizumab program to help elucidate the potential to inhibit both IL-17A and BAFF in a single antibody therapy,” stated Michael Howell, Ph.D., Chief Scientific Officer and Head of Translational Medicine. “We believe that dual-pathway inhibition may warrant broad clinical exploration and help define the expanding potential of ZB-106 across a portfolio of autoimmune diseases.”